These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

458 related articles for article (PubMed ID: 33667349)

  • 1. Extremely potent human monoclonal antibodies from COVID-19 convalescent patients.
    Andreano E; Nicastri E; Paciello I; Pileri P; Manganaro N; Piccini G; Manenti A; Pantano E; Kabanova A; Troisi M; Vacca F; Cardamone D; De Santi C; Torres JL; Ozorowski G; Benincasa L; Jang H; Di Genova C; Depau L; Brunetti J; Agrati C; Capobianchi MR; Castilletti C; Emiliozzi A; Fabbiani M; Montagnani F; Bracci L; Sautto G; Ross TM; Montomoli E; Temperton N; Ward AB; Sala C; Ippolito G; Rappuoli R
    Cell; 2021 Apr; 184(7):1821-1835.e16. PubMed ID: 33667349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potent Neutralizing Antibodies against SARS-CoV-2 Identified by High-Throughput Single-Cell Sequencing of Convalescent Patients' B Cells.
    Cao Y; Su B; Guo X; Sun W; Deng Y; Bao L; Zhu Q; Zhang X; Zheng Y; Geng C; Chai X; He R; Li X; Lv Q; Zhu H; Deng W; Xu Y; Wang Y; Qiao L; Tan Y; Song L; Wang G; Du X; Gao N; Liu J; Xiao J; Su XD; Du Z; Feng Y; Qin C; Qin C; Jin R; Xie XS
    Cell; 2020 Jul; 182(1):73-84.e16. PubMed ID: 32425270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Fc-mediated effector functions of a potent SARS-CoV-2 neutralizing antibody, SC31, isolated from an early convalescent COVID-19 patient, are essential for the optimal therapeutic efficacy of the antibody.
    Chan CEZ; Seah SGK; Chye H; Massey S; Torres M; Lim APC; Wong SKK; Neo JJY; Wong PS; Lim JH; Loh GSL; Wang D; Boyd-Kirkup JD; Guan S; Thakkar D; Teo GH; Purushotorman K; Hutchinson PE; Young BE; Low JG; MacAry PA; Hentze H; Prativadibhayankara VS; Ethirajulu K; Comer JE; Tseng CK; Barrett ADT; Ingram PJ; Brasel T; Hanson BJ
    PLoS One; 2021; 16(6):e0253487. PubMed ID: 34161386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.
    Wang P; Nair MS; Liu L; Iketani S; Luo Y; Guo Y; Wang M; Yu J; Zhang B; Kwong PD; Graham BS; Mascola JR; Chang JY; Yin MT; Sobieszczyk M; Kyratsous CA; Shapiro L; Sheng Z; Huang Y; Ho DD
    Nature; 2021 May; 593(7857):130-135. PubMed ID: 33684923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
    Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
    Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.
    Pinto D; Park YJ; Beltramello M; Walls AC; Tortorici MA; Bianchi S; Jaconi S; Culap K; Zatta F; De Marco A; Peter A; Guarino B; Spreafico R; Cameroni E; Case JB; Chen RE; Havenar-Daughton C; Snell G; Telenti A; Virgin HW; Lanzavecchia A; Diamond MS; Fink K; Veesler D; Corti D
    Nature; 2020 Jul; 583(7815):290-295. PubMed ID: 32422645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A SARS-CoV-2 neutralizing antibody with extensive Spike binding coverage and modified for optimal therapeutic outcomes.
    Guo Y; Huang L; Zhang G; Yao Y; Zhou H; Shen S; Shen B; Li B; Li X; Zhang Q; Chen M; Chen D; Wu J; Fu D; Zeng X; Feng M; Pi C; Wang Y; Zhou X; Lu M; Li Y; Fang Y; Lu YY; Hu X; Wang S; Zhang W; Gao G; Adrian F; Wang Q; Yu F; Peng Y; Gabibov AG; Min J; Wang Y; Huang H; Stepanov A; Zhang W; Cai Y; Liu J; Yuan Z; Zhang C; Lou Z; Deng F; Zhang H; Shan C; Schweizer L; Sun K; Rao Z
    Nat Commun; 2021 May; 12(1):2623. PubMed ID: 33976198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of spike N501Y mutation on neutralizing activity and RBD binding of SARS-CoV-2 convalescent serum.
    Lu L; Chu AW; Zhang RR; Chan WM; Ip JD; Tsoi HW; Chen LL; Cai JP; Lung DC; Tam AR; Yau YS; Kwan MY; To WK; Tsang OT; Lee LL; Yi H; Ip TC; Poon RW; Siu GK; Mok BW; Cheng VC; Chan KH; Yuen KY; Hung IF; To KK
    EBioMedicine; 2021 Sep; 71():103544. PubMed ID: 34419925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potent SARS-CoV-2 neutralizing antibodies with protective efficacy against newly emerged mutational variants.
    Li T; Han X; Gu C; Guo H; Zhang H; Wang Y; Hu C; Wang K; Liu F; Luo F; Zhang Y; Hu J; Wang W; Li S; Hao Y; Shen M; Huang J; Long Y; Song S; Wu R; Mu S; Chen Q; Gao F; Wang J; Long S; Li L; Wu Y; Gao Y; Xu W; Cai X; Qu D; Zhang Z; Zhang H; Li N; Gao Q; Zhang G; He C; Wang W; Ji X; Tang N; Yuan Z; Xie Y; Yang H; Zhang B; Huang A; Jin A
    Nat Commun; 2021 Nov; 12(1):6304. PubMed ID: 34728625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cross-Neutralization of Emerging SARS-CoV-2 Variants of Concern by Antibodies Targeting Distinct Epitopes on Spike.
    Changrob S; Fu Y; Guthmiller JJ; Halfmann PJ; Li L; Stamper CT; Dugan HL; Accola M; Rehrauer W; Zheng NY; Huang M; Wang J; Erickson SA; Utset HA; Graves HM; Amanat F; Sather DN; Krammer F; Kawaoka Y; Wilson PC
    mBio; 2021 Dec; 12(6):e0297521. PubMed ID: 34781736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Impact on Infectivity and Neutralization Efficiency of SARS-CoV-2 Lineage B.1.351 Pseudovirus.
    Kim YJ; Jang US; Soh SM; Lee JY; Lee HR
    Viruses; 2021 Apr; 13(4):. PubMed ID: 33917138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma.
    Andreano E; Piccini G; Licastro D; Casalino L; Johnson NV; Paciello I; Dal Monego S; Pantano E; Manganaro N; Manenti A; Manna R; Casa E; Hyseni I; Benincasa L; Montomoli E; Amaro RE; McLellan JS; Rappuoli R
    Proc Natl Acad Sci U S A; 2021 Sep; 118(36):. PubMed ID: 34417349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intranasal Administration of a Monoclonal Neutralizing Antibody Protects Mice against SARS-CoV-2 Infection.
    Halwe S; Kupke A; Vanshylla K; Liberta F; Gruell H; Zehner M; Rohde C; Krähling V; Gellhorn Serra M; Kreer C; Klüver M; Sauerhering L; Schmidt J; Cai Z; Han F; Young D; Yang G; Widera M; Koch M; Werner A; Kämper L; Becker N; Marlow MS; Eickmann M; Ciesek S; Schiele F; Klein F; Becker S
    Viruses; 2021 Jul; 13(8):. PubMed ID: 34452363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2.
    Chi X; Yan R; Zhang J; Zhang G; Zhang Y; Hao M; Zhang Z; Fan P; Dong Y; Yang Y; Chen Z; Guo Y; Zhang J; Li Y; Song X; Chen Y; Xia L; Fu L; Hou L; Xu J; Yu C; Li J; Zhou Q; Chen W
    Science; 2020 Aug; 369(6504):650-655. PubMed ID: 32571838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of a Broadly Neutralizing Monoclonal Antibody against SARS-CoV-2 Variants.
    Zakir TS; Meng T; Carmen LCP; Chu JJH; Lin RTP; Prabakaran M
    Viruses; 2022 Jan; 14(2):. PubMed ID: 35215823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike.
    Liu L; Wang P; Nair MS; Yu J; Rapp M; Wang Q; Luo Y; Chan JF; Sahi V; Figueroa A; Guo XV; Cerutti G; Bimela J; Gorman J; Zhou T; Chen Z; Yuen KY; Kwong PD; Sodroski JG; Yin MT; Sheng Z; Huang Y; Shapiro L; Ho DD
    Nature; 2020 Aug; 584(7821):450-456. PubMed ID: 32698192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutralizing Monoclonal Antibodies That Target the Spike Receptor Binding Domain Confer Fc Receptor-Independent Protection against SARS-CoV-2 Infection in Syrian Hamsters.
    Su W; Sia SF; Schmitz AJ; Bricker TL; Starr TN; Greaney AJ; Turner JS; Mohammed BM; Liu Z; Choy KT; Darling TL; Joshi A; Cheng KM; Wong AYL; Harastani HH; Nicholls JM; Whelan SPJ; Bloom JD; Yen HL; Ellebedy AH; Boon ACM
    mBio; 2021 Oct; 12(5):e0239521. PubMed ID: 34517754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection.
    Winkler ES; Gilchuk P; Yu J; Bailey AL; Chen RE; Chong Z; Zost SJ; Jang H; Huang Y; Allen JD; Case JB; Sutton RE; Carnahan RH; Darling TL; Boon ACM; Mack M; Head RD; Ross TM; Crowe JE; Diamond MS
    Cell; 2021 Apr; 184(7):1804-1820.e16. PubMed ID: 33691139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutralizing Antibody Responses to SARS-CoV-2 in Recovered COVID-19 Patients Are Variable and Correlate With Disease Severity and Receptor-Binding Domain Recognition.
    Maciola AK; La Raja M; Pacenti M; Salata C; De Silvestro G; Rosato A; Pasqual G
    Front Immunol; 2022; 13():830710. PubMed ID: 35173741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single domain shark VNAR antibodies neutralize SARS-CoV-2 infection in vitro.
    Gauhar A; Privezentzev CV; Demydchuk M; Gerlza T; Rieger J; Kungl AJ; Walsh FS; Rutkowski JL; Stocki P
    FASEB J; 2021 Nov; 35(11):e21970. PubMed ID: 34637549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.